ERBB2 and neoplasm: Therefore, in view of the relevance of this target (currently the only available validated predictive biomarker in GOC) and the challenges related to laboratory assessment of tumour samples in everyday practice,18 we developed and validated an easy-to-use and cheap nomogram, which predicts with high accuracy the chance of HER2 positivity before approved molecular diagnostics such as IHC and ISH are performed.11 Using a cut-off probability as given by the nomogram of 0.2, the test has a sensitivity of 0.82 and a specificity of 0.74 to detect the presence of HER2 positivity.